News Quantified

CYDY – cytodyn inc (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

December 2025 Letter to Shareholders [Yahoo! Finance]

December 2025 Letter to Shareholders

CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium

CytoDyn Announces Resolution of Class Action Lawsuit [Yahoo! Finance]

CytoDyn Announces Resolution of Class Action Lawsuit

Form 424B3 CytoDyn Inc.

Form EFFECT CytoDyn Inc.

Form POS AM CytoDyn Inc.

Form EFFECT CytoDyn Inc.

Form 424B3 CytoDyn Inc.

Top News Gainers

3/30 Three Additional Patients with Severe COVID-19 Treated with Leronlimab in New York Medical Center Bringing the Total to 10 Patients 90.5%

12/19 CytoDyn Inc (OTCMKTS: CYDY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $1.50 price target on the stock, up previously from $1.00. 50.5%

3/27 CytoDyn Files FDA-Suggested Modifications to IND and Protocol for Phase 2 Clinical Trial for COVID-19 Patients with Mild to Moderate Indications and a Second Randomized Protocol for All COVID-19 Patients in Severe Condition Will be Filed Next Week per FDA 46.1%

12/17 CytoDyn Signs Definitive Agreements with Vyera Pharmaceuticals to Commercialize Leronlimab in the U.S. for the Treatment of HIV 38.6%

1/31 CytoDyn Announces Stunning Results from Clinical Trials Evaluating mTNBC and MBC with Leronlimab and will Request an Emergency Type C Meeting with FDA to Enroll 50 Awaiting Patients with a Serious Solid Tumor Cancer Condition 20.2%

4/3 CytoDyn Inc (OTCMKTS: CYDY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock, up previously from $1.50. 18.7%

4/27 CytoDyn Submits Completed Biologics License Application (BLA) to the FDA for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients 17.3%

4/24 CytoDyn to Hold Conference Call to Provide Updates on Completion of BLA Filing for HIV, Timeline for Potential Approval of Treatment for COVID-19 Patients, and Two Publications, Including The New England Journal of Medicine 15.6%

4/1 CytoDyn Files a Clinical Trial Protocol with the FDA to Treat Severely Ill COVID-19 Patients with Leronlimab where the Primary Endpoint is Mortality Rate at Two Weeks 15.2%

5/9 Form 8-K CytoDyn Inc. For: May 08 15.1%

Top News Decliners

4/2 Treatment with CytoDyn's Leronlimab Indicates Significant Trend Toward Immunological Restoration in Severely Ill COVID-19 Patients -23.5%

2/6 CytoDyn Files a Phase 2 Basket Trial with Leronlimab (PRO 140) for Treatment of All Solid Tumor Cancers -11.5%

4/30 Form S-3/A CytoDyn Inc. -8.7%

5/15 CytoDyn Files Pivotal Trial Protocol for HIV Monotherapy with FDA -8.3%

5/22 Form 8-K CytoDyn Inc. For: May 22 -7.5%

5/14 CytoDyn Strengthens Management Team with Key Additions in Business Development and Quality Regulatory Compliance as it Advances Commercialization Plan for Leronlimab -7.4%

3/31 Cytodyn’s Leronlimab Could Be an Answer to COVID-19 [Yahoo! Finance News] -7.0%

4/28 Form 8-K CytoDyn Inc. For: Apr 24 -7.0%

1/2 CytoDyn: Buy, Sell, Or Hold Following PRO 140 Commercial Agreement [Seeking Alpha] -6.7%

4/27 Form 8-K CytoDyn Inc. For: Apr 23 -6.4%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day